M. Goetsch

Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II

S. Vermeire, J. S. Kim, W. Sandborn, 2021, Journal of Crohn's & colitis.

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

S. Vermeire, B. Sands, G. D'Haens, 2023, The Lancet.

Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

S. Vermeire, B. Sands, G. D'Haens, 2023, The Lancet.

P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme

L. Peyrin-Biroulet, I. Modesto, M. Dubinsky, 2023, Journal of Crohn's & Colitis.

P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials

L. Peyrin-Biroulet, S. Danese, J. Panés, 2023, Journal of Crohn's and Colitis.